← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Synthetic anticholinergics, quaternary ammonium compounds
diphemanil
A03AB15
Forms & Strengths
- Topical powder 2%
- Tablet 5 mg
- Topical cream 2%
Adult Dosing
- Hyperhidrosis: Apply topical powder or cream 2 to 3 times daily to affected areas
- Peptic ulcer disease / GI hypermotility: 5 to 10 mg orally 3 to 4 times daily
Pediatric Dosing
- Safety and efficacy in pediatric patients not well established; use generally avoided or restricted in young children
Indications
- Primary and secondary hyperhidrosis
- Adjunctive treatment of peptic ulcer disease and gastrointestinal hypermotility disorders
Mechanism of Action
- Competitive antagonist at peripheral muscarinic acetylcholine receptors (anticholinergic), reducing eccrine sweat gland secretion and gastrointestinal motility/acid secretion
Contraindications
- Glaucoma (angle-closure)
- Gastric retention or pyloric stenosis
- Paralytic ileus or severe ulcerative colitis
- Uropathic obstructive conditions (e.g., prostatic hypertrophy)
- Known hypersensitivity to diphemanil
Adverse Reactions
- Xerostomia (dry mouth)
- Blurred vision and mydriasis
- Constipation and urinary retention
- Tachycardia and palpitations
- Drowsiness and dizziness
- Reduced sweating (risk of hyperthermia in warm environments)
Drug Interactions
- Concomitant use with other anticholinergic agents (e.g., tricyclic antidepressants, antihistamines) enhances anticholinergic toxicity
- May alter gastrointestinal absorption of concurrently administered oral medications due to decreased GI motility
Curated Content: Needs Vetting Before Put to Clinical Use